Literature DB >> 8422903

Effect of riluzole on focal cerebral ischemia in rats.

F Wahl1, M Allix, M Plotkine, R G Boulu.   

Abstract

The effects of riluzole, a putative inhibitor of glutamate release, on the histological and neurobehavioral consequences of middle cerebral artery occlusion were tested in Sprague-Dawley rats. Neurobehavioral studies (neurological examination, passive avoidance task) were carried out with sham-operated and occluded rats. Riluzole 4 and 8 mg/kg administered 30 min after occlusion reduced (P < 0.01) the cortical infarct (respectively 94 +/- 12 mm3 and 73 +/- 15 mm3 versus 139 +/- 8 mm3 for control rats). Striatum necrosis was not modified by the low dosage (46 +/- 3 mm3 versus 49 +/- 3 mm3 for control rats), whereas the high dosage increased it (61 +/- 3 mm3, P < 0.05). The ischemia-induced neurological and memory impairments were not improved by riluzole. Our results indicate that a drug depressing glutamatergic neurotransmission without blocking the glutamate receptors exerts anti-ischemic activity. Moreover, the results highlight the need for carrying out histological and neurobehavioral studies in parallel in this model.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422903     DOI: 10.1016/0014-2999(93)90804-q

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Increased survival and reinnervation of cervical motoneurons by riluzole after avulsion of the C7 ventral root.

Authors:  Sándor Pintér; Balázs Gloviczki; András Szabó; Gábor Márton; Antal Nógrádi
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

Review 2.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Glutamate receptors, neurotoxicity and neurodegeneration.

Authors:  Anthony Lau; Michael Tymianski
Journal:  Pflugers Arch       Date:  2010-03-14       Impact factor: 3.657

Review 4.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases.

Authors:  Hamid Moha ou Maati; Rémi Peyronnet; Christelle Devader; Julie Veyssiere; Fabien Labbal; Carine Gandin; Jean Mazella; Catherine Heurteaux; Marc Borsotto
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

Review 6.  Treatment of acute cerebral ischemia using animal models: a meta-analysis.

Authors:  Peng-Fei Wang; Yu Zhou; Huang Fang; Sen Lin; Yan-Chun Wang; Yong Liu; Jun Xia; Guy D Eslick; Qing-Wu Yang
Journal:  Transl Neurosci       Date:  2015-02-11       Impact factor: 1.757

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.